“Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older.”, Vaccine, vol. S0264-410X, no. 20, pp. 31504-31508, 2021.
, “Vaccine-related major cutaneous reaction size correlates with cellular-mediated immune responses after tularaemia immunisation.”, Clin Transl Immunology, vol. 10, no. 1, p. e1239, 2021.
, “Safety and immunogenicity of three seasonal inactivated influenza vaccines among pregnant women and antibody persistence in their infants.”, Vaccine, vol. 38, no. 33, pp. 5355-5363, 2020.
, “Mupirocin for Decolonization of Infants in Neonatal Intensive Care Units.”, Pediatrics, vol. 143, no. 1, 2019.
, “Antibody responses among adolescent females receiving two or three quadrivalent human papillomavirus vaccine doses at standard and prolonged intervals.”, Vaccine, vol. 36, no. 6, pp. 881-889, 2018.
, “Caregiver and adolescent factors associated with delayed completion of the three-dose human papillomavirus vaccination series.”, Vaccine, vol. 36, no. 11, pp. 1491-1499, 2018.
, “Randomized trial comparing the safety and antibody responses to live attenuated versus inactivated influenza vaccine when administered to breastfeeding women.”, Vaccine, vol. 36, no. 31, pp. 4663-4671, 2018.
, “Safety and immunogenicity of seasonal trivalent inactivated influenza vaccines in pregnant women.”, Vaccine, vol. 36, no. 52, pp. 8054-8061, 2018.
, “B-Cell Responses to Intramuscular Administration of a Bivalent Virus-Like Particle Human Norovirus Vaccine.”, Clin Vaccine Immunol, vol. 24, no. 5, 2017.
, “Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial.”, Vaccine, vol. 35, no. 13, pp. 1675-1682, 2017.
, , “Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine.”, Vaccine, vol. 34, no. 4, pp. 547-554, 2016.
, “Priming Vaccination With Influenza Virus H5 Hemagglutinin Antigen Significantly Increases the Duration of T cell Responses Induced by a Heterologous H5 Booster Vaccination.”, J Infect Dis, vol. 214, no. 7, pp. 1020-9, 2016.
, “Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects.”, Vaccine, vol. 33, no. 39, pp. 5225-34, 2015.
, “Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial.”, JAMA, vol. 314, no. 3, pp. 237-46, 2015.
, “Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations.”, Vaccine, vol. 33, no. 1, pp. 163-73, 2015.
, “Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial.”, J Infect Dis, vol. 212, no. 7, pp. 1032-41, 2015.
, “Sex difference in immune response to vaccination: A participant-level meta-analysis of randomized trials of IMVAMUNE smallpox vaccine.”, Vaccine, vol. 33, no. 41, pp. 5425-5431, 2015.
, “Assessment of congenital anomalies in infants born to pregnant women enrolled in clinical trials.”, Clin Infect Dis, vol. 59 Suppl 7, pp. S428-36, 2014.
, “Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.”, JAMA, vol. 312, no. 14, pp. 1420-8, 2014.
, “A novel intramuscular bivalent norovirus virus-like particle vaccine candidate--reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults.”, J Infect Dis, vol. 210, no. 11, pp. 1763-71, 2014.
, , “Safety and immune responses in children after concurrent or sequential 2009 H1N1 and 2009-2010 seasonal trivalent influenza vaccinations.”, J Infect Dis, vol. 206, no. 6, pp. 828-37, 2012.
, “Immunogenicity of an inactivated monovalent 2009 H1N1 influenza vaccine in pregnant women.”, J Infect Dis, vol. 204, no. 6, pp. 854-63, 2011.
, “Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant.”, J Infect Dis, vol. 203, no. 5, pp. 666-73, 2011.
,